Q2 revenue rises 14%, PAT jumps 30% and margins improve

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

TORNTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.6%Reaction day

₹3581.00

prior close

₹3660.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.3%+6.3% vs market

Pharmaceuticals peers, median of 155sector-0.1%+6.8% vs sector

On the reaction day the stock moved 6.3 pts more than Nifty 100 and 6.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.6

10m

+1.6

15m

+2.0

30m

+2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.6+0.3+6.3-0.1+6.8

Next day

+6.8+0.7+6.0-0.8+7.6

+6.8+1.4+5.4+0.2+6.6

+7.0+1.4+5.7-0.0+7.1

+7.4+1.5+6.0+0.2+7.3

+6.5+1.9+4.6+0.3+6.2

+4.5+1.9+2.6-0.9+5.3

15d

+4.2+2.2+2.0-1.5+5.7

+5.8+0.4+5.4-3.8+9.6

+10.0+0.8+9.2-6.5+16.5

+13.8+1.6+12.2-6.9+20.6

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY26 consolidated revenue rose 14% to Rs. 3,302 crore and operating EBITDA rose 15% to Rs. 1,083 crore. PAT increased 30% to Rs. 591 crore; H1 PAT rose 25%. EBITDA margin edged up to 32.8%. A Rs. 13 crore exceptional charge covered fees for the proposed JB Pharma acquisition. Reports were unqualified.

Likely market impact

Strong profit and margin growth is positive for shares, but the large JB Pharma acquisition creates funding, approval and integration risk.